FCM
Farallon Capital Management Portfolio holdings
AUM
$17.3B
1-Year Est. Return
47.36%
This Fund
S&P 500
1 Year Est. Return
+47.36%
AUM
$17.7B
AUM Growth
-$4.23B
(-19%)
Holding
168
Top Buys
| 1 | +$221M | |
| 2 | +$177M | |
| 3 | +$173M | |
| 4 |
Norfolk Southern
NSC
|
+$171M |
| 5 |
Exelixis
EXEL
|
+$139M |
Top Sells
| 1 | +$3.53B | |
| 2 | +$804M | |
| 3 | +$530M | |
| 4 |
Liberty Broadband Class C
LBRDK
|
+$421M |
| 5 |
ANSS
Ansys
ANSS
|
+$350M |
Sector Composition
| 1 | Healthcare | 45.75% |
| 2 | Technology | 15.89% |
| 3 | Financials | 12.88% |
| 4 | Communication Services | 6.89% |
| 5 | Industrials | 6.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Liberty Broadband Class A
LBRDA
$7.84B
| – | – |
-58,215
|
|
||
|
152
Liberty Broadband Class C
LBRDK
$7.86B
| – | – |
-4,274,445
|
|
||
153
Eli Lilly
LLY
$866B
| – | – |
0
|
|
||
|
PARA
154
DELISTED
Paramount Global Class B
PARA
| – | – |
-1,346,151
|
|
||
155
Invesco S&P 500 Equal Weight ETF
RSP
$88.6B
| – | – |
0
|
|
||
|
SAGE
156
DELISTED
Sage Therapeutics
SAGE
| – | – |
-42,800
|
|
||
157
State Street SPDR S&P 500 ETF Trust
SPY
$689B
| – | – |
-5,500,000
|
|
||
|
THRD
158
DELISTED
Third Harmonic Bio
THRD
| – | – |
-15,361
|
|
||
159
United Therapeutics
UTHR
$21.3B
| – | – |
-1,000
|
|
||
|
VERV
160
DELISTED
Verve Therapeutics
VERV
| – | – |
-3,612,000
|
|
||
|
VRNA
161
DELISTED
Verona Pharma
VRNA
| – | – |
-1,810,000
|
|
||
162
Voyager Therapeutics
VYGR
$214M
| – | – |
-715,000
|
|
||
163
Full Truck Alliance
YMM
$9.3B
| – | – |
-1,550,598
|
|
||
|
BBOT
164
BridgeBio Oncology
BBOT
$795M
| – | – |
-600,000
|
|
||
|
LTM
165
LATAM Airlines Group S.A.
LTM
$14B
| – | – |
-318,092
|
|
||
|
AMED
166
DELISTED
Amedisys
AMED
| – | – |
-575,000
|
|
||
|
SWTX
167
DELISTED
SpringWorks Therapeutics
SWTX
| – | – |
-5,000
|
|